Benjamin Haibe-Kains , PhD

Follow Dr. Haibe-Kains:
Senior Scientist, Princess Margaret Cancer Centre
Keywords: bioinformatics, cancer, genomics, pharmacogenomics, translational research, machine learning
The research performed in the Haibe-Kains Laboratory focuses on the integration of high-throughput data from various sources to simultaneously analyze multiple facets of diseases, with a particular emphasis on cancer. Dr. Haibe-Kains and his team are using publicly available genomic datasets and data generated through his collaboration to better understand the biology underlying diseases and to develop new predictive models in order to significantly improve disease management. Dr. Haibe-Kains's main contributions include several prognostic gene signatures in breast cancer, subtype classification models for ovarian and breast cancers, as well as genomic predictors of drug response in cancer cell lines.

Related Links

Lab Website
Orchestrating a community-developed computational workshop and accompanying training materials.
F1000Res. 2018;7:1656
Davis S, Ramos M, Shepherd L, Turaga N, Geistlinger L, Morgan MT, Haibe-Kains B, Waldron L
Vulnerabilities of radiomic signature development: The need for safeguards.
Radiother Oncol. 2018 Nov 08;:
Welch ML, McIntosh C, Haibe-Kains B, Milosevic MF, Wee L, Dekker A, Huang SH, Purdie TG, O'Sullivan B, Aerts HJWL, Jaffray DA
The Antiarrhythmic Drug, Dronedarone, Demonstrates Cytotoxic Effects in Breast Cancer Independent of Thyroid Hormone Receptor Alpha 1 (THRα1) Antagonism.
Sci Rep. 2018 Nov 08;8(1):16562
Elliott MJ, Jerzak KJ, Cockburn JG, Safikhani Z, Gwynne WD, Hassell JA, Bane A, Silvester J, Thu KL, Haibe-Kains B, Mak TW, Cescon DW
MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis.
Cancer Cell. 2018 Oct 08;34(4):579-595.e8
Tu WB, Shiah YJ, Lourenco C, Mullen PJ, Dingar D, Redel C, Tamachi A, Ba-Alawi W, Aman A, Al-Awar R, Cescon DW, Haibe-Kains B, Arrowsmith CH, Raught B, Boutros PC, Penn LZ
Consensus on Molecular Subtypes of High-grade Serous Ovarian Carcinoma.
Clin Cancer Res. 2018 Jul 03;:
Chen GM, Kannan L, Geistlinger L, Kofia V, Safikhani Z, Gendoo DMA, Parmigiani G, Birrer MJ, Haibe-Kains B, Waldron L
PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies.
Nucleic Acids Res. 2018 Jan 04;46(D1):D994-D1002
Smirnov P, Kofia V, Maru A, Freeman M, Ho C, El-Hachem N, Adam GA, Ba-Alawi W, Safikhani Z, Haibe-Kains B
Gene Expression Signatures Prognostic for Relapse in Stage I Testicular Germ Cell Tumors (TGCT).
BJU Int. 2018 May 03;:
Lewin J, Soltan Ghoraie L, Bedard PL, Hamilton RJ, Chung P, Moore M, Jewett MAS, Anson-Cartwright L, Virtanen C, Winegarden N, Tsao J, Warde P, Sweet J, Haibe-Kains B, Hansen AR
Publisher Correction: ZNF143 provides sequence specificity to secure chromatin interactions at gene promoters.
Nat Commun. 2018 Apr 10;9:16194
Bailey SD, Zhang X, Desai K, Aid M, Corradin O, Cowper-Sal Lari R, Akhtar-Zaidi B, Scacheri PC, Haibe-Kains B, Lupien M
Rational design and identification of immuno-oncology drug combinations.
Eur J Cancer. 2018 Apr 06;95:38-51
Iafolla MAJ, Selby H, Warner K, Ohashi PS, Haibe-Kains B, Siu LL
A review of connectivity map and computational approaches in pharmacogenomics.
Brief Bioinform. 2017 09 01;18(5):903
Musa A, Ghoraie LS, Zhang SD, Glazko G, Yli-Harja O, Dehmer M, Haibe-Kains B, Emmert-Streib F

Pages


 
Senior Scientist, Princess Margaret Cancer Centre

Assistant Professor, Department of Medical Biophysics, University of Toronto
Adjunct Assistant Professor, Department of Computer Science, University of Toronto
Ontario Institute for Cancer Research (OICR) Associate